DFTX · Definium Therapeutics, Inc. · Documents

$33.00 -1.47 (-4.26%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$4.52B

136.90M

Volume · Nov 12 1.2M Avg daily vol (3M) 2M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

2023

Jun 5

Proxy statement DEFA14A

Proxy statement

Jun 5

Proxy statement DEFA14A

Proxy statement

May 31

Proxy statement DEFA14A

Proxy statement

May 31

Proxy statement DEFA14A

Proxy statement

May 25

Proxy statement DEFA14A

Proxy statement

May 25

Proxy statement DEFA14A

Proxy statement

May 25

Proxy statement DEFA14A

Proxy statement

May 24

Current report 8-K

Regulation FD disclosure, Other events

May 24

Proxy statement DEFA14A

Proxy statement

May 22

Proxy statement DEFA14A

Proxy statement

May 18

Proxy statement DEFA14A

Proxy statement

May 17

Current report 8-K

Financial results, Other events

May 12

Proxy statement DEFA14A

Proxy statement

May 12

Proxy statement DEFA14A

Proxy statement

May 12

Proxy statement DEFA14A

Proxy statement

May 9

Proxy statement DEFA14A

Proxy statement

May 4

Earnings call

Q1 2023 earnings call

May 4

Current report 8-K

Financial results

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $24.82M Diluted EPS -$0.65

May 4

Proxy statement DEFA14A

Proxy statement

May 2

Proxy statement DEFA14A

Proxy statement

May 2

Proxy statement DEFA14A

Proxy statement

May 2

Proxy statement DEFA14A

Proxy statement

May 1

Annual report to holders ARS

Annual report to holders

Apr 18

Current report 8-K Events of Apr 15

Director or officer change, or executive pay

Apr 18

Current report 8-K

Other events

Apr 18

Proxy statement DEFA14A

Proxy statement

Apr 14

Current report 8-K

Regulation FD disclosure, Other events

Mar 13

Current report 8-K

Other events

Mar 9

Earnings call

Q4 2022 earnings call

Mar 9

Current report 8-K

Financial results

Mar 9

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $56.8M Diluted EPS -$1.84

Jan 9

Current report 8-K

Other events

2022

Nov 10

Earnings call

Q3 2022 earnings call

Nov 10

Current report 8-K

Financial results

Nov 10

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $16.49M Diluted EPS -$0.56

Sep 29

Current report 8-K Events of Sep 27

Entered into a material agreement, Other events

Sep 14

Current report 8-K Events of Sep 13

Other events

Aug 26

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure

Aug 11

Current report 8-K

Financial results, Director or officer change, or executive pay

Aug 11

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $16.96M Diluted EPS -$0.04

Jul 21

Current report 8-K

Regulation FD disclosure, Other events

Jun 30

Current report 8-K

Charter or bylaw amendment, or fiscal year change

Jun 2

Current report 8-K Events of May 27

Delisting notice or listing transfer, Shareholder vote results

May 23

Current report 8-K

Director or officer change, or executive pay

May 19

Current report 8-K

Regulation FD disclosure, Other events

May 16

Current report 8-K

Financial results

May 16

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $18.45M

May 13

Proxy statement DEFA14A

Proxy statement

May 11

Current report 8-K

Regulation FD disclosure

Showing 101–150 of 207 documents

Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 192 filings 190 filers Visit website Investor relations